| Recruiting | 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacemen Hypogonadism, Male | Phase 3 | 2025-03-07 |
| Terminated | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Extrahepatic | Phase 1 | 2017-10-02 |
| Terminated | A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compa Pancreatic Ductal Carcinoma | Phase 3 | 2016-03-14 |
| Completed | A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selecte NSCLC, Gastric Cancer | Phase 1 | 2015-10-22 |
| Terminated | A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects Wi Non-small Cell Lung Cancer | Phase 1 | 2015-02-10 |
| Completed | A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Type 1 Diabetes Mellitus | Phase 4 | 2013-10-03 |
| Completed | PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants Wit Metastatic Pancreatic Cancer | Phase 2 | 2013-05-14 |
| Completed | CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadminist Type 1 Diabetes Mellitus | Phase 4 | 2013-03-01 |
| Completed | Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers Healthy | Phase 1 | 2012-02-01 |
| Completed | Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluron Type 1 Diabetes Mellitus | Phase 4 | 2011-12-01 |
| Completed | Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer Stage IV Pancreatic Cancer | Phase 1 / Phase 2 | 2011-09-01 |
| Completed | Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneo Type 1 Diabetes Mellitus | Phase 1 | 2011-01-01 |
| Completed | Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patient Diabetes Mellitus, Type II | Phase 2 | 2010-08-01 |
| Completed | Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Partici Diabetes Mellitus, Type 1 | Phase 2 | 2010-08-01 |
| Completed | Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Solid Tumor | Phase 1 | 2010-07-01 |
| Completed | A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared Healthy | Phase 1 | 2009-09-01 |
| Completed | Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Diabetes Mellitus, Type 2 | Phase 2 | 2009-07-01 |
| Completed | Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatit Dermatitis, Allergic Contact | Phase 2 | 2009-06-23 |
| Completed | Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Parti Diabetes Mellitus, Type 1 | Phase 2 | 2009-05-01 |
| Completed | Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombin Diabetes Mellitus | Phase 1 | 2009-03-01 |
| Completed | Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors Solid Tumor | Phase 1 | 2009-02-01 |
| Completed | Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonat Risk Factors for or a Diagnosis of Osteoporosis | Phase 1 | 2008-12-01 |
| Completed | Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Ad Healthy Volunteers | Phase 1 | 2008-11-01 |
| Completed | Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladde Superficial Bladder Cancer | Phase 1 | 2008-10-01 |
| Completed | Subcutaneous Rehydration Compared to Intravenous Rehydration Dehydration | Phase 4 | 2008-10-01 |
| Completed | Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus Type 1 Diabetes Mellitus | Phase 2 | 2008-10-01 |
| Completed | Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Diabetes Mellitus | Phase 1 | 2007-12-01 |
| Completed | Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex) Healthy | Phase 4 | 2007-12-01 |
| Completed | A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase Healthy | Phase 1 | 2007-02-01 |
| Completed | Study of a Large Protein Molecule Administered With Escalating Doses of Recombinant Human Hyaluronidase Rheumatoid Arthritis | Phase 4 | 2006-07-01 |
| Completed | Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants Wit Bladder Cancer | Phase 1 / Phase 2 | 2006-03-30 |
| Completed | INFUSE Morphine Study Pain | Phase 3 | 2006-01-01 |
| Completed | A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase Healthy | Phase 4 | 2005-11-01 |